Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
9 May 24
DEFA14A
Additional proxy soliciting materials
7 May 24
8-K
Departure of Directors or Certain Officers
7 May 24
EFFECT
Notice of effectiveness
23 Apr 24
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
PRE 14A
Preliminary proxy
5 Apr 24
S-8
Registration of securities for employees
19 Mar 24
S-3
Shelf registration
19 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
19 Mar 24
D
Exempt offering of security
13 Feb 24
8-K
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
5 Feb 24
8-K
Other Events
1 Feb 24
8-K
Other Events
22 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
7 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
26 Oct 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
2 Jun 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights
4 May 23
ARS
2022 FY
Annual report to shareholders
17 Apr 23
DEFA14A
Additional proxy soliciting materials
17 Apr 23
DEF 14A
Definitive proxy
17 Apr 23
10-K
2022 FY
Annual report
22 Mar 23
8-K
Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights
22 Mar 23
8-K
Departure of Directors or Certain Officers
1 Mar 23
8-K
Other Events
29 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights
3 Nov 22
EFFECT
Notice of effectiveness
14 Oct 22
CORRESP
Correspondence with SEC
11 Oct 22
UPLOAD
Letter from SEC
11 Oct 22
8-K
Entry into a Material Definitive Agreement
3 Oct 22
S-3
Shelf registration
3 Oct 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
Latest ownership filings
4
Susan Moran
9 May 24
3
Susan Moran
9 May 24
4
Stephen Michael Rothenberg
9 May 24
3
Stephen Michael Rothenberg
9 May 24
4
Alan Fuhrman
19 Mar 24
4
Hiroomi Tada
19 Mar 24
4
Todd Harris
19 Mar 24
4
Daniel Bensen
13 Mar 24
SC 13G/A
FMR LLC
11 Mar 24
4
Daniel Bensen
8 Mar 24
4
Daniel Bensen
5 Mar 24
4
Daniel Bensen
29 Feb 24
4
Daniel Bensen
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
144
Notice of proposed sale of securities
12 Feb 24
4
Daniel Bensen
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Peter Kolchinsky
8 Feb 24
SC 13D/A
Boxer Capital, LLC
8 Feb 24
4
JOSEPH LEWIS
8 Feb 24
4
Daniel Bensen
6 Feb 24
4
Todd Harris
6 Feb 24
144
Notice of proposed sale of securities
6 Feb 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
6 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
4
Hiroomi Tada
19 Sep 23
4
Todd Harris
19 Sep 23
4
Alan Fuhrman
19 Sep 23
4
Hiroomi Tada
1 Aug 23
4
Todd Harris
1 Aug 23
4
Alan Fuhrman
1 Aug 23
4
Daniel Bensen
1 Aug 23
4
Daniel Bensen
21 Jul 23
4
Daniel Bensen
17 Jul 23
4
Daniel Bensen
12 Jul 23
4
Daniel Bensen
3 Jul 23
4
Daniel Bensen
28 Jun 23
4
Todd Harris
26 Jun 23
144
Notice of proposed sale of securities
23 Jun 23